Beta cells are the insulin-producing cells of the pancreatic islets of Langerhans, accounting for 60 to 80 percent of islet cells. They are destroyed by autoimmunity in type 1 diabetes, with roughly 80 to 90 percent function lost by the time of clinical diagnosis. In type 2 diabetes, beta-cell function declines progressively — roughly 50 percent at diagnosis and 25 percent at 6 years according to the UK Prospective Diabetes Study (UKPDS). Understanding beta-cell biology — how they sense glucose, secrete insulin, and fail — underpins emerging therapies including teplizumab, verapamil, GLP-1 agonists, and stem cell-derived islet replacement.
What Beta Cells Are
- Endocrine cells in the islets of Langerhans
- 60 to 80 percent of islet cells in healthy adults
- Approximately 1 million islets in the human pancreas
- Concentrated in the body and tail of the pancreas
- Total beta-cell mass roughly 1 to 1.5 grams in a healthy adult
- Produce, store, and secrete insulin in response to glucose
Other Islet Cells
| Cell Type | Hormone | Function |
|---|---|---|
| Beta cells (60 to 80%) | Insulin, amylin | Lower blood glucose; suppress glucagon |
| Alpha cells (15 to 20%) | Glucagon | Raise blood glucose |
| Delta cells (5 to 10%) | Somatostatin | Suppress insulin and glucagon |
| PP cells | Pancreatic polypeptide | Modulates gastric and pancreatic secretion |
| Epsilon cells | Ghrelin | Appetite signaling |
How Beta Cells Make Insulin
- Insulin gene transcribed to preproinsulin mRNA
- Translated into preproinsulin and processed in the endoplasmic reticulum to proinsulin
- Proinsulin folded with disulfide bonds linking A and B chains
- Cleaved by prohormone convertases PC1/3 and PC2 to insulin and C-peptide
- Stored in secretory granules as hexamers with zinc
- Released by exocytosis when glucose-stimulated insulin secretion (GSIS) is triggered
For a deeper look at insulin biology, see how insulin works.
Beta-Cell Failure in Type 1 Diabetes
Mechanism
- Autoimmune attack by CD4 and CD8 T cells targeting beta-cell antigens
- Insulitis — immune infiltration of islets
- Autoantibodies against GAD-65, IA-2, ZnT8, insulin, and islet cell components
- Genetic susceptibility from HLA-DR3 and HLA-DR4, plus dozens of non-HLA loci
- Environmental triggers — enteroviruses, microbiome, possibly other infections
Time Course
- Pre-clinical phase can last months to years
- Stage 1: 2 or more autoantibodies, normal glucose
- Stage 2: 2 or more autoantibodies, dysglycemia
- Stage 3: clinical diabetes
- By stage 3, roughly 80 to 90 percent of beta-cell function is lost
- Residual C-peptide may persist for years and is clinically important
Why Residual Beta-Cell Function Matters
- Better glycemic control
- Lower hypoglycemia risk
- Possibly lower complication risk
- Target of disease-modifying therapy
Beta-Cell Failure in Type 2 Diabetes
Functional Defects
- Loss of first-phase insulin secretion early in disease
- Impaired glucose sensing
- Reduced incretin responsiveness
- Increased proinsulin-to-insulin ratio
- Loss of pulsatile insulin secretion
Cellular Stressors
- Glucotoxicity — chronic high glucose damages beta cells
- Lipotoxicity — chronic high free fatty acids
- Endoplasmic reticulum stress
- Oxidative stress
- Inflammation
- Islet amyloid deposition (from amylin)
Beta-Cell Mass vs Function in Type 2
Whether type 2 diabetes is primarily a beta-cell mass problem (cell loss) or function problem (cells present but underperforming) is debated. Most evidence suggests both — modest reductions in mass plus substantial functional impairment. Some defective cells may have undergone dedifferentiation, losing beta-cell identity rather than dying.
UKPDS Trajectory
| Time Point | Approximate Beta-Cell Function |
|---|---|
| Onset of insulin resistance | Above 100% (compensating) |
| Prediabetes | ~80% |
| Diagnosis of type 2 diabetes | ~50% |
| 6 years after diagnosis | ~25% |
Beta-Cell Apoptosis Pathways
- Death receptor (Fas) pathway in type 1 autoimmunity
- ER stress-induced apoptosis under glucotoxic and lipotoxic conditions
- Mitochondrial pathway
- Inflammatory cytokine-mediated death
- TXNIP (thioredoxin-interacting protein) as a key glucose-induced apoptotic mediator — verapamil reduces TXNIP and shows preservation of beta-cell function in recent type 1 trials
Therapies Targeting Beta Cells
Disease-Modifying in Type 1
- Teplizumab — anti-CD3 monoclonal antibody, first FDA-approved therapy to delay onset of stage 3 type 1 diabetes
- Verapamil — calcium channel blocker, preserved C-peptide in a phase 2 trial
- Anti-thymocyte globulin (ATG), low-dose IL-2, and other immunomodulators under investigation
- Antigen-specific tolerance approaches in trials
Beta-Cell Preservation in Type 2
- GLP-1 receptor agonists may improve beta-cell function
- Pioglitazone improves insulin sensitivity, indirectly easing beta-cell workload
- Early intensive treatment in newly diagnosed type 2 may preserve function (e.g., short courses of insulin)
- Bariatric surgery can improve beta-cell function substantially
Beta-Cell Replacement
- Whole-pancreas transplantation — typically for type 1 patients receiving simultaneous kidney transplant
- Islet transplantation — donor islets infused into the hepatic portal vein; requires immunosuppression
- Stem cell-derived islet therapy (e.g., VX-880) — early trials show insulin independence in some recipients
- Encapsulated islet approaches to avoid immunosuppression — research stage
Markers of Beta-Cell Mass and Function
| Test | What It Measures |
|---|---|
| Fasting C-peptide | Basal insulin secretion |
| Stimulated C-peptide (MMTT) | Maximum insulin reserve |
| Insulin secretion rate (clamp studies) | Research-grade function |
| HOMA-B | Calculated index of beta-cell function |
| Proinsulin-to-insulin ratio | Beta-cell stress indicator |
| OGTT-derived indices | Disposition index combines secretion and sensitivity |
Lifestyle Factors and Beta-Cell Function
- Weight loss improves beta-cell function in type 2, sometimes substantially
- Physical activity improves insulin sensitivity, reducing beta-cell workload
- Reduced refined carbohydrate intake reduces postprandial glucose excursions and stress
- Sleep quality affects beta-cell function
- Smoking accelerates beta-cell decline
What Patients Can Take From This
- Type 1 diabetes is a disease of beta-cell destruction; lifelong insulin is needed
- Type 2 diabetes is a disease of progressive beta-cell decline, not just insulin resistance
- Early intensive treatment may preserve more beta-cell function
- Disease-modifying therapies (teplizumab) and beta-cell replacement (stem cell-derived islets) are emerging
- Lifestyle still matters at every stage of beta-cell decline
Related Reading
See our companion pieces on how insulin works, what causes diabetes, diabetes classification, and our prediabetes basics hub.
The Bottom Line
Beta cells are the insulin-producing cells of the pancreatic islets. Their autoimmune destruction causes type 1 diabetes — roughly 80 to 90 percent of function is lost by the time symptoms appear. In type 2 diabetes, beta-cell function declines progressively from approximately 50 percent at diagnosis to 25 percent at 6 years, driven by glucotoxicity, lipotoxicity, ER stress, and inflammation. Emerging therapies including teplizumab, verapamil, GLP-1 receptor agonists, and stem cell-derived islet replacement aim to preserve, restore, or replace beta cells. Lifestyle, early intensive treatment, and ongoing research all matter for protecting the cells that produce insulin.
